New research article
A competitive BB-ELISA for anti-toxin B neutralising antibodies in assessing risk of recurrent Clostridioides difficile infection: a retrospective cohort study from the MODIFY I and II trials

New research article
A competitive BB-ELISA for anti-toxin B neutralising antibodies in assessing risk of recurrent Clostridioides difficile infection: a retrospective cohort study from the MODIFY I and II trials
Our results demonstrate that a combinatorial immune-microbiota-based approach can treat infections. This is just the trailer, stay tuned for the final show!! Real team effort, I am grateful to all people involved in this study @upenn.edu #Immunotherapy #Microbiome #MicrobiotaBasedTherapy #Cdiff
🦠🧬 #Cdiff can rapidly alter its gene activity when threatened, helping the #intestinal #pathogen withstand hostile conditions ...
#Clostridioides #Microbes #Bacteria #Microbiome #Microsky via @sciencex.bsky.social
The Peggy Lillis Foundation will host its annual Changing the Odds Gala this month, and it will include a casino, fellowship amongst the #Cdiff community, and an award ceremony. #IDsky #Medsky
www.contagionlive.com/view/peggy-l...
🦠 #Clostridioides difficile does not cause symptoms in #infants – but that does not mean the #bacteria are harmless: new research led by @joeyzacks.bsky.social from 🇺🇸 @childrensphila.bsky.social links colonization to serious long-term consequences for the developing gut. #CDiff #pediatrics